Inflammation can be prevented in most inflammatory brain diseases, while tissue repair of the lesioned central nervous system (CNS) is still a major challenge. The CNS is difficult to access for protein therapeutics due to the blood-brain barrier. Here, we show that genetically engineered embryonic stem cell-derived microglia (ESdM) are a suitable therapeutic vehicle for neurotrophin-3 (NT3) in experimental autoimmune encephalomyelitis (EAE). The intravenously transplanted ESdM migrated into the inflammatory CNS lesions and engrafted there as microglial cells. EAE afflicted mice treated with ESdM that were genetically modified to express NT3 showed stable recovery from disease symptoms. The NT3-transduced ESdM created an anti-inflammatory cytokine milieu in the spinal cord and promoted neuronal sprouting. Furthermore, mice treated with NT3-transduced ESdM showed less axonal injury and reduced demyelination. Thus, genetically modified ESdM represent a suitable tool to introduce therapeutic neuroprotective and repair-promoting proteins into the CNS in neuroinflammatory diseases.
INTRODUCTION
Exploiting gene therapy to treat central nervous system (CNS) diseases affecting the whole organ is still a major challenge. Even in mice, gene therapy vectors can hardly target the entire cerebral cortex or spinal cord. For more than a decade, potential use of circulating immune cells that can specifically home to sites of CNS pathology has been proposed as a possible solution to this gene delivery problem. 1, 2 Recently, several groups have analyzed the homing and therapeutic potential of monocytes or other bone marrow-derived myeloid cells for CNS lesions. Blood monocyte-derived macrophages showed a beneficial impact on the clinical course of spinal cord injury and promoted an anti-inflammatory milieu at the injury site in spinal cord-lesioned mice. 3 Monocyte-derived macrophages with a CD115 þ CD11b þ Ly6C þ phenotype invaded the lesioned retina to become CD11b þ CX3CR1 þ macrophages and also showed neuroprotective activity on retinal ganglion neurons. 4 Kigerl et al. 5 showed in a model of spinal cord injury that a M1-polarized macrophage response overwhelms a comparatively smaller and transient M2-polarized macrophage response at sites of traumatic spinal cord injury, suggesting that M2 macrophage polarization might promote CNS repair. Furthermore, bone marrow-derived myeloid precursor cells genetically engineered to overexpress the microglial triggering receptor expressed on myeloid cells 2 (TREM2) ameliorated the clinical symptoms and reduced axonal damage and demyelination in experimental autoimmune encephalomyelitis (EAE). 6 All these studies demonstrated that bone marrow myeloid precursor cells and blood monocyte-derived macrophages were capable of migrating to traumatic or inflammatory lesion sites in the CNS. However, these invaded bone marrow-derived cells were clearly different in respect to their origin from resident microglial cells, which populate the CNS as primitive macrophages originating from the yolk sac at embryonic day 7.5. Later during embryonic development, these primitive macrophages locally proliferate within the CNS to finally become microglia. [7] [8] [9] [10] Furthermore, it is questionable whether invaded blood or bone marrow-derived cells stably engraft into the CNS as microglial cells. Recent data demonstrated that blood-derived monocytes infiltrating the brain during EAE do not contribute to the resident microglia pool in the CNS, 11, 12 which casts some doubt onto using this cell type for long-term cell therapy of inflammatory CNS diseases. Thus, microglial cells are unique and cannot easily be replaced by other hematopoietic cells for a long-lasting cell and gene therapy approach.
Recently, a method for generation of microglial cells derived from embryonic stem (ES) cells was described to circumvent the problem of limited access to this cell type. [13] [14] [15] The ES cell-derived microglial (ESdM) precursors were obtained by a classical differentiation protocol for the derivation of neuronal cells from ES cells. 16 This protocol mimics normal brain development from embryoid bodies, which shows both in parallel neurogenesis and yolk sac-like hematopoiesis. 17 Thus, ESdM appear to co-develop in a mixed neural culture from ES cells through a yolk sac-like primitive macrophage intermediate, which very much reflects the in vivo situation of microglial development. As there is an urgent need for targeting biologics to the diseased CNS, we asked whether ESdM could serve as a natural cellular vehicle for CNS cell and gene therapy. The potential of ESdM in therapeutical approaches for neuroinflammatory and neurodegenerative diseases is further underlined by the role of microglia in the progression of these diseases. 18 Thus, microglia cells are a promising prospect not only as delivery vehicle but also as therapeutic target cells themselves. Here, we provide experimental evidence that microglial cells obtained from ES cells migrate and engraft into the CNS after intravenous transplantation in EAE and show growth-promoting activity after lentiviral transduction with the neurotrophic factor neurotrophin-3 (NT3).
RESULTS

Characterization of microglial precursors derived from ES cells
Mouse ESdM were obtained from a C57/BL6 ES cell line accordingly to a method established in our laboratory. 15 The ES cells were first differentiated into embryoid bodies and then into a mixed culture mainly consisting of neural precursor cells. Then neuronal precursors differentiated into neurons, astrocytes, and small colonies of Iba1 þ and CD45 þ cells that were isolated and propagated to obtain stably proliferating ESdM. Analysis of ESdM by flow cytometry showed expression of CD11b, CD11c, CD29, CD45, CD49d, CD68, CD80, CD86, CD115, F4/80, TREM2, MHC (major histocompatibility complex) class II and CX3CR1. No expression of the stem cell markers CD34, CD133 and cKit were detected on ESdM by flow cytometry analysis. Interestingly, ESdM showed no expression of the inflammatory monocyte markers C-C motif chemokine receptor 2 (CCR2) and Ly6G as well as no CD31 (Supplementary Figure S1 ).
Migration and engraftment of microglial precursors into spinal cord lesions Next, ESdM were lentivirally transduced with green fluorescent protein (GFP) and 4 Â 10 6 GFP-ESdM were transplanted intravenously in adult C57BL/6 mice. The percentage of GFP-ESdM in distinct organs was determined by flow cytometry at 4 and 24 h after transplantation. At 4 h, GFP-ESdM were observed in the lung (4.75 ± 0.33%), blood (0.84 ± 0.55%), spleen (0.71 ± 0.62%) and liver (1.67±1.82%), but not in the bone marrow, spinal cord or brain ( Figure 1a , black bars). After 24 h, GFP-ESdM were only detected in the spleen (0.70 ± 0.72%) and liver (0.60 ± 0.65%; Figure 1a , black bars). Thus, GFP-ESdM failed to enter and home to the CNS of healthy adult mice.
EAE was induced in C57BL/6 mice by immunization with a myelin oligodendrocyte glycoprotein (MOG) peptide. Now, the GFP-ESdM transplanted at the peak of EAE disease symptoms were detected in the spinal cord. In detail, GFP-ESdM transplanted on day 20 of EAE were present in the spinal cord after 4 h (0.46 ± 0.38%) and after 24 h (0.76 ± 0.31%). Migration to other organs during EAE was comparable with that observed in healthy mice ( Figure 1a , red bars). Thus, GFP-ESdM migrated into inflammatory spinal cord lesions after intravenous transplantation in EAE mice but had no significant effect on the clinical score of EAE (Figure 1b) .
Fluorescence imaging was performed to detect the transplanted GFP-ESdM in the spinal cord lesions. At 24 h after transplantation of GFP-ESdM on day 20 in EAE-afflicted mice, numerous GFP-ESdM were found close to inflammatory lesions in the spinal cord (Figure 2b were observed, the number increased at day 10 after transplantation to 74 ± 23 and at day 21 after transplantation to 88 ± 30 GFP þ cells mm À 2 (Figure 2c ). Flow cytometrical analysis of cultured GFP-ESdM in comparison to ex vivo isolated GFP-ESdM from spinal cords after intravenous transplantation in EAE mice revealed that a subpopulation of GFP þ cells showed a reduced expression level of CD45 in the spinal cord (ratio median fluorescent intensity CD45/isotype 6.52 ± 0.71) compared with cultured GFP-ESdM (ratio median fluorescent intensity CD45/ isotype 52.15±6.74; Figures 2d and e) . Furthermore, GFP-ESdM showed no proliferative phenotype in the spinal cord as they completely lost their immunostaining for the proliferative marker Ki-67 (data not shown). Thus, transplanted GFP-ESdM engrafted as Iba1 þ , CD45 þ and CD11b þ cells within the lesioned tissue of the spinal cord. Reduced CD45 expression and loss of proliferation indicates an adaption towards a resident microglial phenotype.
Gene transfer of NT3 into microglial precursors NT3 was shown to act neuroprotective 19 and has been chosen as representative neurotrophic factor for lentiviral transduction. The mouse NT3 gene was cloned into a lentiviral vector under the phosphoglycerate kinase (pgk)-promoter and then used for detected in the supernatants of control GFP-ESdM, the supernatants of NT3-GFP-ESdM contained 214.67 ± 17.09 pg ml À 1 NT3. Gene transcripts for NT3 were detected via reverse transcriptase (RT)-PCR in NT3-GFP-ESdM but not in the control GFP-ESdM (Supplementary Figure S2c) . The cytokine profile of GFP-ESdM or NT3-GFP-ESdM was analyzed by quantitative RT-PCR under normal and inflammatory conditions. The NT3-GFP-ESdM showed no significant difference in the constitutive and lipopolysaccharideinduced gene transcription of the pro-inflammatory mediators inducible nitric oxide synthase, tumor necrosis factor-a and interleukin-1b as well as in transforming growth factor-b1 (Supplementary Figure S3) . Thus, ESdM transduced with NT3 kept their typical cytokine profile.
Clinical improvement of EAE after transplantation of NT3-transduced microglial precursors Next, 4 Â 10 6 NT3-GFP-ESdM were transplanted in EAE-afflicted mice on day 20 post disease induction. As controls, 4 Â 10 6 GFPESdM or phosphate-buffered saline (PBS) were applied. EAE mice treated with NT3-GFP-ESdM recovered and showed less severe disease symptoms ( Figure 3a and Table 1 ). Although the cumulative disease score from days 1-20 was similar between all the groups (16.9 ± 2.1 for NT3-GFP-ESdM-treated mice; 15.9±2.4 for GFP-ESdM-treated mice and 14.3±2.7 for PBStreated mice), it decreased from 55.7±8.1 after PBS application to 44.4 ± 10.9 after therapy of mice with NT3-GFP-ESdM ( Table 1) . The GFP-ESdM had no significant effect on the clinical symptoms of the mice compared with PBS ( Figure 3a) . The cumulative disease score of mice treated with GFP-ESdM was 54.7±5.0 compared with 55.7 ± 8.1 after PBS application (Table 1) . Interestingly, NT3-GFP-ESdM-treated mice showed continuous recovery, while mice which received PBS typically displayed a disease course with remittent recovery. In detail, intermediate deteriorations in the disease score were observed in 18.2% of the PBStreated group, 9.1% of the GFP-ESdM-treated group and only 4.5% of the NT3-GFP-ESdM-treated group.
Thus, intravenous treatment with NT3-GFP-ESdM had a beneficial effect on the clinical score that was still present up to several weeks post application.
Ameliorated demyelination and less axonal injury after transplantation of NT3-transduced microglia On day 40 after EAE induction, mice were perfused, and spinal cords were analyzed to assess any tissue damage. No significant differences in the number of MAC-3 þ macrophages/activated microglia, and CD3 þ T cells were observed between the mice treated with GFP-ESdM, NT3-GFP-ESdM or PBS ( Figure 3b and Supplementary Figure S4 ). However, staining of myelin with luxol fast blue (LFB) revealed less demyelination in the NT3-GFP-ESdMtreated mice (31.8 ± 2.8%) compared with the PBS controls (44.6 ± 3.5%; Figures 4a and c). Additionally, paraffin slices were stained for amyloid precursor protein (APP) to determine axonal injury ( Figure 4b ). Axonal damage was decreased in mice treated with NT3-GFP-ESdM (25.1 ± 2.1%) in comparison to PBS-treated control mice (38.8 ± 3.2%; Figure 4c ). Overall, histology showed less myelin loss and less axonal degeneration after therapy with NT3-transduced ESdM.
Anti-inflammatory cytokine milieu induced in the spinal cord by NT3-transduced microglia Analysis of the cytokine profile in the spinal cord and spleen was performed via quantitative RT-PCR at 4 days after cell transplantation. NT3-GFP-ESdM induced an anti-inflammatory cytokine milieu in the spinal cord by decreasing gene transcription of inducible nitric oxide synthase from 0.325 ± 0.039 to 0.002 ± 0.001, for tumor necrosis factor-a from 0.411±0.038 to 0.110±0.037 and for interleukin-1b from 0.382±0.027 to 0.148±0.029 compared with GFP-ESdM-treated mice (Figure 5a) . Interestingly, the anti-inflammatory cytokine interleukin-10 was increased in NT3-GFP-ESdM from 0.710 ± 0.044 to 3.111 ± 0.639 compared with GFP-ESdMtreated mice (Figure 5a ). Analysis of NT3 in the spinal cord confirmed increased gene transcription (approximately 10-fold) after therapy with NT3-GFP-ESdM (Figure 5a ). Such changes to an anti-inflammatory cytokine milieu were not observed in the spleen indicating lesion-associated effects of the transplanted NT3-GFPESdM (Figure 5b ). Data demonstrated that the NT3-transduced ESdM completely changed the cytokine milieu at the spinal cord lesion site, with reduced gene transcription of pro-inflammatory and increased transcription of anti-inflammatory cytokines.
Repair-promoting effect of NT3-transduced microglia in inflammatory EAE lesions To test whether NT3-GFP-ESdM produce bioactive and functional NT3, embryonic dorsal root ganglia (DRG) were obtained and Figures 5a and b) . Data demonstrated that NT3-transduced ESdM promoted neurite growth in vitro.
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Immunostaining of GAP43 was performed in the spinal cord of EAE mice to demonstrate the growth-promoting activity of the ex vivo NT3 gene therapy approach. Treatment of EAE with NT3-GFP-ESdM resulted in a strong staining for GAP43 in the white matter of the spinal cord nearby the invaded NT3-GFP-ESdM (Figure 6c ). Strong immunostaining for GAP43 was already detectable within the inflammatory spinal cord lesions on day 1 after treatment with NT3-GFP-ESdM and remained elevated over the next 3 weeks. Only very few GAP43-positive cells were detectable in tissue samples taken from GFP-ESdM or PBS-treated mice (Figure 6d) . Thus, NT3-transduced ESdM not only created a beneficial inflammatory cytokine profile but also stimulated expression of molecules involved in cellular outgrowth.
DISCUSSION
Cell-based treatments for multiple sclerosis (MS) gained major attention during recent years. In animal experiments with EAE, the main research focused on hematopoietic stem cells, mesenchymal stem cells (MSCs) and neural stem cells (NSCs). Especially MSCs and NSCs were shown to have robust therapeutic effects in both rodents and primates EAE models. 20 Furthermore, reconstitution of myeloablated mice with hematopoietic stem cells showed beneficial effects in EAE, although success of this approach appeared to be limited to early disease stages. 21 The potential of MSCs was rather attributed to their secretion of immunomodulatory factors having anti-inflammatory effects than to their physical contribution to cell repair. 22 NSCs had been proposed to act as vehicle for trophic factors but were also shown to have beneficial effects after systemic administration via an immuno-suppressive mechanism. 23, 24 Furthermore, MSCs and NSCs did not reach the CNS easily. Therefore, they were often administered directly into the CNS. 25 Thus, several reasons favor ESdM as therapeutic stem cell-derived tool. Firstly, ESdM underwent, in contrast to bone marrow-derived myeloid cells, a developmental program similar to microglia. Microglia have been shown to originate from the primitive hematopoiesis of the yolk sac, 7, 8 an intermediate stage that is reproduced in culture during differentiation of ES cells. 17, 26 This is further supported by the cell surface markers of ESdM (CD45 þ , CD11b þ , CD115 þ , CX3CR1 þ , F4/80 þ , c-Kit À , CD31 À ) that are identical to the yolk sac-derived primitive macrophages described as 'second wave' by Bertrand et al. 27 Secondly, ESdM transplanted intravenously overcame the blood-brain barrier and specifically migrated to the lesion sites after CNS injury. After induction of inflammatory spinal cord lesions by MOG antigen immunization, ESdM were able to migrate to the lesion sites after intravenous application. By contrast, in the adult healthy mouse, no CNSdirected migration of ESdM was observed. Thus, a lesion-associated trigger was sufficient to attract the ESdM to a focal site in the CNS. Thirdly, ESdM stably engrafted into the CNS of EAE mice. ESdM were detected for 21 days after transplantation in the EAE spinal cord lesions, whereas bone marrow-derived cells were shown to disappear from the spinal cord after 4 days. 6 Moreover, ESdM showed a cell marker profile similar to resident microglia (CD45 low , CD11b þ and Iba1 þ ) and like resident microglia lacked any signs of proliferation. 28 Thus, ESdM in contrast to monocytes or bone marrow-derived cells are integrating as an organ-resident cell type, a prerequisite for long-term gene therapy. 29 Finally, ESdM are, in contrast to inflammatory monocytes, polarized towards a more beneficial subtype. ESdM express CX3CR1, but lack expression of CCR2 and Gr1/Ly6G, thus showing certain overlap with the regulatory monocyte 30 or the M2-polarized macrophage subtype. 31 This is also reflected in our experiments, where ESdM without genetic modification showed a minor, but not significant, beneficial effect on the clinical score of EAE. In contrast, inflammatory monocytes express CCR2 and are closely associated with disease progression of EAE. 11, 12 To further improve the beneficial effect of ESdM, we genetically modified the cells with a prototypic neurotrophin having neuroprotective and neuroregenerative capacity. Caggiula et al. 32 already suggested neurotrophins as promising candidates for regenerative therapeutic approaches of MS based on the direct association between the high neurotrophin level and complete remission of MS in the post-relapse phase. Additionally, neurotrophins were shown to be endogenously expressed by T cells and other immune cells at the lesion sites in human MS. 33 As inflammatory lesions in EAE are mainly located in the spinal cord, we selected NT3 as neurotrophin for the ex vivo gene transfer in ESdM. After spinal cord injury, injection of NT3, but not brain-derived neurotrophic factor, into the lesion site was found to enhance regenerative sprouting in the corticospinal tract and to improve neural repair. 34 Furthermore, introduction of a NT3 gradient via lentiviral vectors into spinal cord lesions was shown to increase the number of ascending sensory axons extending into Stem cell-derived microglia as therapeutic vehicle C Beutner et al the lesion sites. 35 Interestingly, NT3 is also produced during EAE by infiltrating T cells and natural killer cells that already might potentially promote neuronal protection during the disease course. 36 In our experiments, no differences were found in the number of infiltrating T cells, thus the different levels of NT3 measured in the spinal cord were most probably due to the secretion of NT3 by the NT3-GFP-ESdM.
Furthermore, we demonstrated that NT3, locally produced by the NT3-GFP-ESdM, had growth-promoting activity through upregulation of GAP43 in the inflammatory spinal cord lesions.
NT3 is closely linked to the survival and functional maintenance of neuronal subpopulations. 37 NT3 interacts with the tyrosine-related kinase C receptor with high affinity 38 and stimulates axonal outgrowth, neurogenesis and neural survival. 39, 40 In vitro experiments showed that treatment with supernatant from NT3-GFP-ESdM resulted in an induction of GAP43 comparable with the treatment with 10 ng ml À 1 of recombinant NT3. Interestingly, NT3-GFP-ESdM not only had regenerative activity as determined by GAP43 immunostaining but also an antiinflammatory effect in EAE. The NT3-transduced ESdM changed Stem cell-derived microglia as therapeutic vehicle C Beutner et al the cytokine profile in the spinal cord from a pro-inflammatory to an anti-inflammatory milieu. This change in the cytokine profile should have substantial consequences as the local cytokine micromilieu has been shown to determine the outcome of the inflammatory process in EAE. [41] [42] [43] Treatment of EAE-afflicted mice with NT3-GFP-ESdM also improved the demyelination pattern of the CNS. Recently, Olah et al. 44 have performed a gene analysis of microglia in the different stages of a cuprizone model and suggested a microglia phenotype which acts in favor of remyelination. They showed that in the recovery phase, microglia express MHCII, CD11c and CD86 but not CD80. Except for CD80, we found a similar profile on the ESdM, which thus might enhance remyelination through oligodendrocytes.
Thus, data demonstrate that ESdM transplanted intravenously home to the lesioned CNS and act as vehicle for neurotrophin release in EAE lesions, leading to a change in the cytokine micromilieu and an activation of regenerative signs. As microglia might also be obtained from human-induced pluripotent stem cells, this novel cell and gene approach might be an alternative to bone marrow-derived monocytes and opens up new therapy strategies for repair of the lesioned CNS in MS and other neuroinflammatory diseases. Nevertheless, the method described here involves genetic modification of the cells, which might limit their application in humans. Furthermore, induced pluripotent stem cells are typically obtained by viral vectors for reprogramming for pluripotency. These obstacles have to be overcome to consider human pluripotent stem cell-derived microglia as a potential applicable therapeutic tool.
MATERIALS AND METHODS
Culture of ESdM derived from ES cells
ESdM were generated from C57BL/6 ES cells (ATCC number SCRC-1002) as previously described 14, 15 and cultured in Dulbecco's modified Eagle's medium/F12 with 1% N2 supplement, 0.48 mM L-Glutamine (all Invitrogen; Life Technologies, Karlsruhe, Germany), 15.3 mg ml À 1 D-glucose (Sigma Aldrich, Steinheim, Germany) and 100 mg ml À 1 penicillin/streptomycin (Invitrogen). Cells were splitted using a cell scraper (Sarstedt, Nü mbrecht, Germany) after reaching confluency of B80%. ESdM with a passage number between 6 and 20 were used in the experiments. All ESdM lines used in this project were confirmed to have identical marker profile expression. For in vitro experiments, ESdM lines 23 and 25 and, for in vivo experiments, ESdM lines 16 and 23 were used.
Flow cytometry analysis of microglial precursors and dissociated tissue cells
ESdM were collected from the culture dish by a cell scraper. Tissue was mechanically dissociated by trituration. Erythrocytes were removed from blood, bone marrow, spleen and liver by hypotonic lysis. ESdM or dissociated tissue cells were washed several times in PBS. Fc-receptor block was performed using CD16/CD32 antibody (BD Biosciences, Heidelberg, Germany) and then cells were stained with either biotin-conjugated antiCD11b, anti-CD45, anti-CD80, anti-CD86, anti-I-A b (MHC class II), anti-c-kit (all BD Biosciences), anti-F4/80, anti-CD34, (all AbD Serotec, Dü sseldorf, Germany), anti-Ly6G (Abcam; Acris, Hiddenhausen, Germany), anti-CD115, anti-CD133 (eBioscience, Frankfurt am Main, Germany) followed by phycoerythrin-conjugated streptavidin (Jackson ImmunoResearch, Suffolk, UK). Furthermore, rat monoclonal anti-CD29, anti-CD49 (all BD Bioscience), anti-CD68 (AbD Serotec), anti-Trem2 (R&D Systems) or rabbit monoclonal anti-CX3CR1 (ProSci Inc.) and anti-CCR2 (Abcam) were used, followed by phycoerythrin-conjugated anti-rat (Jackson ImmunoResearch) or anti-rabbit IgG (Jackson ImmunoResearch). Isotype-matched control antibodies (BD Biosciences) were used as negative controls. Analysis was done with a FACScalibur flow cytometer and FlowJo Software (BD Biosciences).
Lentiviral vector system and cell transduction Lentiviral vectors of the third generation (pLenti6/V5, Invitrogen) were used for transduction of ESdM. The CMV promoter in the pLenti6/V5 vector was replaced by a phosphoglycerate kinase (pgk) promoter. The murine NT3 or GFP genes were cloned independently behind the pgk-promoter, and the neomycin resistance gene was added behind a second pgkpromoter. Cloned sequences were confirmed by automated sequencing (Seqlab, Gö ttingen, Germany). Lentivirus production was performed as described previously. 6 Titers of concentrated viral particles ranged between 1 Â 10 8 and 1 Â 10 9 transducing units ml À 1 . Lentiviral particles and 6 mg ml À 1 polybrene (Sigma Aldrich) were added to the cultured ESdM. The transduced ESdM were purified by flow cytometry sorting (BD Biosciences) or selected via neomycin.
Primary cell culture of neurons
Primary hippocampal neuronal cultures were prepared from hippocampi of C57BL/6 mice embryos (E15-E16) as previously described. 45 Briefly, hippocampi were isolated, dispersed mechanically and seeded at a density of 2.5 Â 10 5 cells per well on culture dishes pretreated with poly-L-ornithine (0.01 mg ml 1% bovine calf serum (fetal bovine serum, PAN Systems, Aidenbach, Germany). Cells were cultured for 5-9 days to obtain morphologically mature neurons. Purity was determined by double immunofluorescence staining for b-tubulin-III (1:500, Sigma Aldrich) together with antibodies directed against GFAP (Dako, Hamburg, Germany) or Iba1 (Wako, Neuss, Germany). DRG were prepared from 13-day-old mice embryos derived from pregnant C57BL/6 mice. DRG were plated in 24-well-plates in neural BME culture medium supplemented with 1% fetal bovine serum, 1% glucose and 2% B27 supplement (all Invitrogen).
Immunostaining and analysis of cultured cells
For immunocytochemical analysis, cells were fixed with 4% paraformaldehyde (PFA), washed and blocked. For detection of NT3, cells were incubated with a primary antibody for NT3 (Santa Cruz Biotech, Heidelberg, Germany) at 4 1C over night, labeled with Cy3-conjugated secondary antibody and co-stained with DAPI (4,6-diamidino-2-phenylindole; Sigma Aldrich). For Ki-67 analysis, cells were incubated with primary antibodies against Ki-67 (Millipore, Schwalbach, Germany) and CD11b (BD Pharmingen, BD Bioscience, Heidelberg, Germany) for 1 h at 4 1C, then labeled with Cy3-(for Ki-67) or Cy5-conjugated antibodies (for CD11b) for 2 h at room temperature and co-stained with DAPI (Sigma Aldrich). For detection of neurite outgrowth from DRG, cells were incubated with an antibody directed against b À tubulin-III (Sigma Aldrich) followed by Cy3-conjugated secondary antibody. The length of the neurite outgrowth was determined by ImageJ software (NIH, http://rsbweb.nih.gov/ij/). For detection of GAP43, hippocampal neurons were double-labeled with antibodies against GAP43 (Dako) and b-tubulin-III (Sigma Aldrich). Relative number of GAP43-positive neurites was assessed by counting the whole number of neurites and neurites stained for GAP43 with an intensity above a set threshold using ImageJ software. For quantification of neurite outgrowth, five randomly selected areas were analyzed by fluorescence microscopy. The b-tubulin-III-positive neurites that crossed two of four 500-mm-long parallel lines (distance of 100 mm between each line) were counted. Filtered cell culture supernatant of NT3-GFP-ESdM or GFP-ESdM (diluted 1:10 with neural medium), recombinant mouse NT3 (10 ng ml À 1 , R&D Systems) or medium alone as control were added to the DRG or hippocampal neurons for 4 h. In five randomly chosen areas, neurons that stained with an intensity above a set threshold were counted using ImageJ software.
RT-PCR and real-time RT-PCR analysis of gene transcripts RNA of cells treated with lipopolysaccharides (500 ng ml À 1 , Sigma Aldrich) or control cells was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). For isolation of RNA from tissue, mice were killed, tissue samples were collected, homogenized in PBS and centrifuged. Cell pellets were resuspended in lysis buffer. Phenol (200 ml) was added and suspension was centrifuged for 15 min at 12 000 r.p.m. Afterwards, aqueous phase was recollected, equal volume of 70% ethanol was added and samples were transferred to RNeasy-column. Reverse transcription of RNA was performed with SuperScript III reverse transcriptase (Invitrogen) and hexamer random primers (Roche Molecular Biochemicals). PCR was performed by amplification with specific oligonucleotides. Quantitative RT-PCR was done with specific oligonucleotides and SYBR Green on an ABI Prism 5700 Sequence Detection System (Perkin Elmer, Rodgau-Jü gesheim, Germany). Amplification of GAPDH was used for sample normalization. The amplification protocol for the GeneAmp 5700 Sequence Detection System Software (v. 1.3; Perkin Elmer) was performed.
ELISA
For measurement of NT3 released in the supernatant, 1 Â 10 6 ESdM, GFPESdM or NT3-GFP-ESdM were cultured for 24 h in 2 ml medium. Supernatants were filtered (0.45 mm) and directly used for ELISA. Mouse Neurotrophin-3 ELISA Kit (Syd Labs, Inc.) was carried out according to the manufacturer's protocol. Color development was monitored with a Perkin Elmer EnVision 2104 Multilabel Reader at 450 nm.
EAE induction and cell transplantation
Adult 6-8 weeks-old female C57BL/6 mice (Charles River, Sulzfeld, Germany) were immunized with 100 mg of MOG (amino acids 35-55; Seqlab) in incomplete Freunds adjuvant (both DIFCO; BD GmbH, Heidelberg, Germany). Pertussis toxin (200 ng; List Biological Laboratories, Epsom, UK) was injected on days 0 and 2 of immunization. Clinical signs were scored as following: 0, no clinical signs; 1, complete limp tail; 2, complete limp tail and weakness of hindlimbs; 3, paraparesis of at least one hindlimb; 4, complete hindlimb paraparesis and weakness of forelimbs; and 5, fore-and hindlimb paralysis or moribund. Only mice having disease onset (clinical score of X1) on day 14 and a clinical score of at least 3 on day 18 were used for experiments. GFP-ESdM, NT3-GFP-ESdM or vehicle control (PBS) were intravenously injected under light anesthesia in EAE mice at day 12 (reflecting the time of first clinical symptoms) or day 20 (reflecting the time of maximum disease symptoms) after disease induction. A remittent recovery was defined as an improvement of at least one clinical score point for at least 2 days with a following deterioration of one clinical score point.
Immunofluorescence staining of EAE spinal cord sections Animals were killed and transcardially perfused with PBS followed by 4% PFA. After post-fixation in fresh fixative, tissue was cryoprotected at 4 1C in PBS containing 2% DMSO and 10% glycerol. Tissue was embedded in OCT (Sakura, Staufen, Germany), frozen on dry ice and stored at À 80 1C before cryosectioning on a Leica CM1900 cryostat (Leica Microsystems, Wetzlar, Germany) at À 20 1C. For staining, sections were fixed in 4% PFA for 1 h. Immunostaining was performed with purified polyclonal rabbit antibody directed against Iba1 (Wako), with monoclonal antibody directed against CD45 (BD Bioscience) or GAP43 (Sigma Aldrich) and a secondary fluorescence Cy3-conjugated antibody (Dianova, Hamburg, Germany).
For quantification of stained or GFP þ cells, five randomly selected areas were analyzed by fluorescence microscopy and Image J software. For Ki-67 analysis, slices were blocked and then incubated with primary antibodies against Ki-67 (Millipore) and CD11b (BD Pharmingen) for 1 h at 4 1C, labeled with Cy3-(for Ki-67) or Cy5-conjugated antibodies (for CD11b) for 2 h at room temperature and co-stained with DAPI (Sigma Aldrich).
Immunohistochemistry of spinal cord EAE tissue
Histological examination of immune cell infiltrates, axonal injury and demyelination were performed as described previously. 46 In brief, mice were perfused with 4% PFA at indicated time points. After removal of the spinal cord and fixation in 4% PFA, spinal cord was dissected and embedded in paraffin. After microwave pretreatment in 10 mM citric acid, the following antibodies were used for immunohistochemical analysis of the spinal cord tissue: monoclonal rat anti-mouse MAC-3 (BD Bioscience) for macrophage staining, monoclonal rat anti-human/mouse CD3 (AbD Serotec) for T cells and monoclonal mouse anti-APP (Chemicon, Hofheim, Germany) for axonal degeneration. The following secondary antibodies were utilized: for CD3 and MAC-3 a biotinylated goat anti-rat immunoglobuline (Amersham Biosciences, Freiburg, Germany) and for APP immunohistochemistry was processed by using the avidin-biotin amplification bridge method with peroxidase as a substrate. Inflammatory spinal cord lesions were defined in each animal on the basis of the MAC3 staining and further analyzed by immunohistochemistry and LFB staining.
The number of MAC-3-positive cells, CD3-positive cells, APP and dMBPpositive deposits, SMI-positive axons and the level of demyelination in LFB staining were quantified using a microscope (Olympus BX51, Hamburg, Germany) equipped with a digital camera (SIS Color View; Soft Imaging System GmbH, Mü nster, Germany) attached to a computer with a software for image analysis (analySIS; Soft Imaging System, www.soft-imaging.net). Decreased LFB staining represents either demyelination or loss of myelin due to axonal destruction. For quantification of LFB staining, three cross sections with the strongest infiltrate of each animal were taken for further analysis of immunohistochemical and LFB stainings. The number of positive cells per square millimeter was calculated, and the total white matter and demyelinated areas were quantified on a computerized imaging system by planimetry. The area of demyelination was expressed as a percentage of the total area of the white matter. Increased local expression of APP as an early and sensitive marker of axonal injury was quantified by counting the number of APP deposits (brown patches) per square millimeter.
Flow cytometry of transplanted GFP-ESdM
Mice were perfused with 1 Â HBSS (Gibco, Life Technologies) for comparison of microglial markers on cultured GFP-ESdM versus GFP-ESdM isolated from spinal cords 4 days after transplantation of GFP-ESdM into EAE mice at day 20 after EAE induction. Spinal cords were collected and homogenized. The suspension was centrifuged for 7 min at 300 g. Pellets were resuspended in 37% Percoll (GE Healthcare, Mü nchen, Germany) and added to a Percoll gradient consisting of 1 Â HBSS, 30% Percoll, 37% Percoll and 70% Percoll from top to down. After a centrifugation step of 40 min at 200 g without brake, the 37-70% interphase was collected and washed with 1 Â HBSS for three times. GFP-ESdM were collected from the culture dish and washed with 1 Â HBSS. Cells were stained with V450-conjugated anti-CD45 (BD Horizon, BD Bioscience) and phycoerythrinconjugated anti-CD11b (BD Pharmingen) antibodies. Isotype-matched control antibodies (BD Horizon and BD Pharmingen) were used as negative control. Analysis was done with a BD LSR II or FACSCanto flow cytometer and FlowJo Software (all BD Biosciences). For analysis of microglial markers, only GFP þ cells were used.
Statistical analysis
Data are presented as mean þ s.e.m. of at least three independent experiments. Data were analyzed by analysis of variance followed by Bonferroni for more than two groups and Student's t-test for two groups only.
